Royal Bank Of Canada Annovis Bio, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.82 - $18.01 $327 - $1,224	68 Added 1700.0%	72 $0
Q1 2024 Nov 05, 2024	SELL	$8.47 - $18.93 $575 - $1,287	-68 Reduced 94.44%	4 $0
Q1 2024 May 15, 2024	SELL	$8.47 - $18.93 $304 - $681	-36 Reduced 90.0%	4 $0
Q3 2023 Nov 14, 2023	SELL	$9.37 - $14.12 $843 - $1,270	-90 Reduced 69.23%	40 $0
Q2 2023 Aug 14, 2023	BUY	$11.95 - $16.31 $1,553 - $2,120	130 New	130 $1,000
Q3 2022 Nov 14, 2022	BUY	$10.26 - $21.81 $41 - $87	4 New	4 $0
Q1 2022 May 16, 2022	SELL	$11.84 - $19.78 $35 - $59	-3 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$17.58 - $37.67 $52 - $113	3 New	3 $0

1.17M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $48.7M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.